13th Jul 2026 11:20
(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Monday.
----------
Main Market small-cap winners
----------
DeFi Development Corp UK PLC, up 18% at 20.00p
Cloudbreak Discovery PLC, up 11% at 0.50p
Nostrum Oil & Gas PLC, up 10% at 3.50p
Robert Walters PLC, up 9.1% at 91.90p
Nanoco Group PLC, up 8.2% at 2.705p
----------
Main Market small-cap losers
----------
First Class Metals PLC, down 9.1% at 2.50p
Aquila European Renewables PLC, down 8.8% at 14.00p
capAI PLC, down 8.5% at 0.56p
abrdn Property Income Trust Ltd, down 7.5% at 1.85p
Cizzle Biotechnology PLC, down 6.4% at 2.20p
----------
AIM winners
----------
Mothercare PLC, up 25% at 0.875p
Physiomics PLC, up 16% at 0.55p
Proteome Sciences PLC, up 15% at 1.95p
CloudCoCo Group PLC, up 9.1% at 0.18p
SysGroup PLC, up 9.1% at 24.00p
----------
AIM losers
----------
Ixico PLC, down 14% at 8.00p, two programmes discontinued reduce order book by GBP1.5m over next 2 years
ProService Building Services Marketplace PLC, down 12% at 2.1975p
Forgent PLC, down 9.4% at 0.0145p
Ukrproduct Group Ltd, down 8.7% at 5.50p
Selkirk Group PLC, down 6.9% at 1.70p
----------
Small-cap and AIM movers in focus:
----------
Ixico PLC, down 14% at 8.00 pence, 12-month range 6.26p-15.00p. Says the discontinuation of two Huntington's disease programmes by existing clients reduces its contracted order book by around GBP1.5 million over the next two financial years. The neuroscience imaging company notes it secures GBP8.0 million of new Huntington's disease programme awards in the first half and says its order book remains 21% above the end of financial 2025. It adds that programme cancellations are a normal feature of drug development and reiterates recently upgraded guidance for financial 2026 and its outlook for 2027.
----------
First Development Resources PLC, up 7.6% at 2.85 pence, 12-month range 2.00p-9.80p. Begins its phase I reverse circulation drilling programme at the Lander West gold target within its Selta project in Australia's Northern Territory. The exploration campaign comprises up to 3,000 metres of drilling to test multiple high-priority gold targets identified through geological mapping, geochemistry and geophysical surveys, with subsequent drilling guided by results from the initial holes.
----------
Richmond Hill Resources PLC, up 5.7% at 1.40 pence, 12-month range 0.73p-3.20p. Completes field reconnaissance and rock sampling at its Martello project in Ontario, Canada, identifying evidence of multiple quartz vein systems at the Sakoose target. The exploration company says the programme supports the area's prospectivity and will help refine targets for future exploration.
----------
Genedrive PLC, down 3.9% at 1.23 pence, 12-month range 0.23p-1.43p. Expects financial 2026 revenue of around GBP1.4 million, up from about GBP1.0 million a year earlier and in line with board expectations, as adoption of its MT-RNR1 and CYP2C19 genetic tests expands across the NHS and international markets. The diagnostics company says it is in its strongest commercial and operational position to date, with more than 20 UK neonatal intensive care units now using its MT-RNR1 test, while maintaining progress on NHS implementation, international expansion and its US regulatory strategy despite delaying its planned FDA 510(k) submission.
----------
Pennant International Group PLC, up 11% at 31.00 pence, 12-month range 17.00p-31.00p. Expects revenue for the six months ended June 30 to rise 31% to around GBP5.9 million from GBP4.5 million, with adjusted Ebitda improving to GBP500,000 from a GBP1.0 million loss a year earlier, as margins strengthen and recurring software revenue grows. The systems support and training solutions provider says it remains on track to meet full-year market expectations. CEO Phil Walker says: "The first half of 2026 demonstrates the progress Pennant is making both strategically and financially as we execute our strategy. Revenue, margin and profitability have all improved significantly, while the successful launch of Auxilium phase 3 and a number of strategic contract wins have strengthened our position in key markets."
----------
By Eva Castanedo, Alliance News senior economics reporter
Comments and questions to [email protected]
Copyright 2026 Alliance News Ltd. All Rights Reserved.
Related Shares:
Pennant InternationalGenedriveFirst Development ResourcesIxicoSelkirk GroupUkrproductForgentProservice BldgDAIP.LCloudCoCoProteomePhysiomicsMothercareCizzle BiotechAbrdn PropertyCapaiAquila Euro.Aquila Euro.First Class Metals PLCNanocoNostrum Oil&gasRobert WaltersCloudbreakDefi Dev Corp